National_Coverage_Determinations_Manual / Positron Emission Tomography FDG for Oncologic Conditions 220.6.17

Why This Topic Matters

FDG PET coverage in oncology affects reimbursement, documentation, and whether services must be billed under national coverage rules or supported by prospective clinical research. Understanding the policy helps organizations avoid incorrect claims handling and align ordering, billing, and compliance workflows with CMS requirements.

Article Sections

1. General

   Introduces the CMS reconsideration of FDG PET coverage for oncologic conditions and the broader coverage framework used in the manual.

2. Framework

   Describes the revised coverage framework and the date on which the updated approach applies to claims.

3. Initial Anti-tumor Treatment Strategy

   Explains the scope of initial-treatment coverage and the exceptions and special handling CMS applies for selected tumor types.

4. Subsequent Anti-tumor Treatment Strategy

   Summarizes coverage for later treatment-related uses of FDG PET and the circumstances under which coverage may occur through prospective clinical studies.

5. Synopsis of New Framework

   Presents the consolidated coverage summary across cancer types and shows how the revised framework classifies each major category.